Tyra Bioscience, Inc ( (TYRA) ) has released its Q2 earnings. Here is a breakdown of the information Tyra Bioscience, Inc presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tyra Biosciences, Inc. is a clinical-stage biotechnology company based in Carlsbad, California, focused on developing next-generation precision medicines targeting fibroblast growth factor receptor (FGFR) biology for oncology and genetically defined conditions. The company leverages its proprietary SNÅP platform to design drugs that address acquired resistance to existing therapies.
In its second quarter 2025 earnings report, Tyra Biosciences highlighted significant advancements in its clinical programs, particularly the dosing of the first patient in the SURF302 study for intermediate-risk non-muscle invasive bladder cancer. The company reported cash, cash equivalents, and marketable securities totaling $296.3 million, which are expected to support operations through at least 2027.
Key financial metrics for the quarter included a net loss of $28.1 million, an increase from $18.7 million in the same period of 2024, driven by higher research and development expenses associated with the progression of clinical trials such as BEACH301 and SURF302. The company also reported increased general and administrative expenses due to personnel-related costs.
Strategically, Tyra Biosciences is advancing its lead candidate, dabogratinib, in multiple clinical studies targeting FGFR3-driven conditions, including bladder cancer and achondroplasia. The company is also progressing with other investigational therapies, TYRA-430 and TYRA-200, aimed at addressing unmet needs in cancer treatment.
Looking ahead, Tyra Biosciences remains focused on delivering meaningful clinical outcomes from its ongoing trials, with anticipated data readouts in 2026. The company is well-positioned financially and strategically to continue its development efforts in precision medicine.